Business
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, Aug.
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy \nNEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard® Esophageal DNA test as a non-invasive triage tool to significantly increase the positive yield of invasive upper endoscopy (EGD) for detection of esophageal precancer (Barrett's Esophagus or BE) and cancer. The manuscript entitled Enhancing the Positive Predictive Value of EGD for Diagnosis of Barrett's Esophagus Through EsoGuard® Triage, is currently available on the leading health sciences preprint server, MedRxiv, while undergoing peer review for publication. Patients triaged to invasive EGD following a positive non-invasive EsoGuard test had a 2.4-fold increase in the positive yield of those EGDs compared to the expected yield of screening EGD alone in at-risk patients.\n\n \n \n \n \n \n \n\n \n\"Up to 90% of esophageal cancer patients were never previously diagnosed with esophageal precancer,\" said ENVET-BE investigator Jayde E. Kurland, M.D., FACG, AGAF, a gastroenterologist and advanced endoscopist at Gastro Health in Lima, OH. \"We found we were missing ~80% of patients in our busy endoscopy practice who should be eligible for esophageal precancer screening based on risk factors and gastroenterology guidelines. This study demonstrates that EsoGuard triage allows us to efficiently screen more patients, significantly improves the yield of endoscopy, and increases our ability to diagnose and treat disease before it develops into cancer. We have fully incorporated EsoGuard in our practice and believe it will serve a crucial role in esophageal precancer screening.\"\nEGD confirmed a BE diagnosis in 50 of the 199 patients in a real-world commercial setting who underwent clinically directed EsoGuard testing and received a positive EsoGuard result. This represents a post-triage EGD yield of 25%, a 2.4-fold increase over the expected 11% yield of EGD as a standalone screening tool in the at-risk population. These findings are consistent with thos...